Pilot projects within the UAB P30 Center contribute to multidisciplinary research on our campus, enhance faculty development, extensively utilize Scientific Cores, and integrate well with the global research themes of the UAB Center. A strong and well-supported Pilot and Feasibility mechanism has allowed the Center to address new research priorities and expand its scientific purview. The goals of the P30 Pilot and Feasibility Component are delineated through four Specific Aims. First, the Pilot Program identifies and supports new research projects of outstanding quality and innovation. Projects typically last one to two years each, are concordant with the overall objectives of the UAB P30, and are intended to result in further grant support from NIH, Cystic Fibrosis (CF) Foundation, or other funding agencies. Second, the Pilot Program supports promising junior faculty in career development through funding of outstanding pilot research. The Center Enrichment Program, strong mentoring within the CF Center, a robust Enrichment program, and extensive training resources available at UAB through the Center for Clinical and Translational Science (UAB's NIH-funded CTSA research program) are also employed toward this end. Third, the Pilot Program augments the breadth and quality of CF research by funding innovative projects from established researchers with valuable expertise who are new to CF research, or alternatively from established CF investigators who want to test new high-impact hypotheses. And fourth, the Pilot Program provides an administrative framework for review and oversight of Pilot and Feasibility Studies. This includes broad solicitation and rigorous peer review of Pilot applications, recommendations regarding 2nd-year funding of Pilots to the Internal Advisory Committee, assistance and mentoring to pilot PIs, and record-keeping with regard to publication and grant outcomes that result from pilot funding to provide evidence for continuous process improvement. Overall, the Pilot Program has had a important impact on CF research at UAB, has been very successful in assisting multiple faculty early in their careers to successfully obtain extramural funding for CF research, and has enlarged our Research Base in new innovative directions.
| Heltshe, Sonya L; Rowe, Steven M; Skalland, Michelle et al. (2018) Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement. Am J Respir Crit Care Med 197:1483-1486 |
| Guimbellot, Jennifer; Solomon, George M; Baines, Arthur et al. (2018) Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros : |
| Cho, Do-Yeon; Lim, Dong-Jin; Mackey, Calvin et al. (2018) Preclinical therapeutic efficacy of the ciprofloxacin-eluting sinus stent for Pseudomonas aeruginosa sinusitis. Int Forum Allergy Rhinol 8:482-489 |
| Raju, S Vamsee; Rowe, Steven M (2018) Not simply the lesser of two evils. Am J Physiol Lung Cell Mol Physiol 314:L236-L238 |
| Peabody, Jacelyn E; Shei, Ren-Jay; Bermingham, Brent M et al. (2018) Seeing cilia: imaging modalities for ciliary motion and clinical connections. Am J Physiol Lung Cell Mol Physiol 314:L909-L921 |
| Davies, Jane C; Moskowitz, Samuel M; Brown, Cynthia et al. (2018) VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med 379:1599-1611 |
| Keating, Dominic; Marigowda, Gautham; Burr, Lucy et al. (2018) VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med 379:1612-1620 |
| Tipirneni, Kiranya E; Zhang, Shaoyan; Cho, Do-Yeon et al. (2018) Submucosal gland mucus strand velocity is decreased in chronic rhinosinusitis. Int Forum Allergy Rhinol 8:509-512 |
| Serocki, Marcin; Bartoszewska, Sylwia; Janaszak-Jasiecka, Anna et al. (2018) miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target. Angiogenesis 21:183-202 |
| Brand, Jeffrey D; Lazrak, Ahmed; Trombley, John E et al. (2018) Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis. JCI Insight 3: |
Showing the most recent 10 out of 175 publications
